The ability of different forms of myelin peptides to induce tolerance for the treatment of preestablished murine experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis, was evaluated. i.v. administration of myelin peptidepulsed, ethylene carbodiimide-fixed syngeneic splenocytes, but not soluble myelin peptide monomers or oligomers, proved exceedingly effective at treating preestablished EAE, resulting in amelioration of disease progression. In addition to the lack of therapeutic efficacy of soluble peptide and peptide oligomer, administering them i.v. after the onset of clinical symptoms in many but not all peptide-induced EAE models led to a rapid-onset anaphylactic reaction characterized by respiratory distress, erythema, decreased body temperature, unresponsiveness, and, often, death. By using anti-IgE antibody treatments and mice with targeted mutations of the Fc␥RIII ␣-chain or the common ␥-chain of FcRI and Fc␥RI͞III, we demonstrate that IgE crosslinking of FcRI appears to be necessary and sufficient for myelin peptide-induced anaphylaxis. The implications of these findings to myelin peptide͞ protein tolerance strategies for the treatment of multiple sclerosis are discussed.
M
ultiple sclerosis (MS) is a CNS-demyelinating disease characterized by the perivascular infiltration of inflammatory mononuclear cells (1) . Although the etiology of MS is unknown, evidence from human patients (2) (3) (4) and an animal model of MS, experimental autoimmune encephalomyelitis (EAE) (5-7), supports a major pathogenic role for autoreactive myelin-specific CD4 ϩ T cells, which are a logical target for clinical therapies. Two protocols that have shown promise in inducing antigen-specific immune tolerance for the prevention and͞or treatment of EAE are the i.v. injection of soluble protein, peptide, or peptide oligomers (8) (9) (10) and the i.v. injection of myelin proteins or peptides chemically coupled to syngeneic splenocytes [antigen-coupled splenocytes (Ag-SP)] (11). We performed a side-by-side comparison of these two tolerance protocols in preventing EAE induction and ameliorating ongoing EAE. We found that i.v. injection of soluble peptide monomer was not particularly effective when administered at any time point tested, and a soluble peptide oligomer was only fully effective when administered after immunization (day ϩ7) but before the onset of clinical symptoms of EAE. In contrast, i.v. administration of Ag-SP proved effective at preventing the onset of clinical symptoms and treating preestablished disease. In addition, an unexpected result of the administration of soluble peptide and peptide oligomer after the onset of clinical symptoms in many, but not all, peptide-induced EAE models was a rapid-onset anaphylactic reaction characterized by respiratory distress, erythema, decreased body temperature, unresponsiveness, and often death. This result is especially alarming given the proposed use of peptide-based tolerance therapies for the treatment of autoimmune diseases.
Anaphylaxis is an acute, life-threatening phenomenon that is usually but not always immune-mediated (12) . The most comprehensively described mechanism of anaphylaxis involves the crosslinking of IgE bound to FcRI on mast cells, leading to the release of preformed mediators, such as histamine, heparin, and tryptase; lipid-derived mediators, such as prostaglandins, leukotrienes, and platelet-activating factor; and cytokines. Collectively, these mediators initiate rapid vascular permeability, leading to plasma extravasation, tissue edema, bronchoconstriction, mucous overproduction, and leukocyte recruitment (13, 14) . In rodents, mast cell degranulation, temperature loss, and mortality associated with active systemic anaphylaxis can also be mediated through the crosslinking of IgG1 bound to Fc␥RIII (15, 16) . We show that the crosslinking of FcRI appears to be necessary and sufficient in myelin peptide-induced anaphylaxis induced by the i.v. injection of soluble peptide or peptide oligomer on or after the peak of acute disease.
Materials and Methods
Mice. Female mice (age, 5-7 weeks) were purchased from the following commercial sources: SJL mice were from Harlan Laboratories (Bethesda, MD); B10.PL, C57BL͞6, and Fc␥RIII␣ knockout (KO) mice on the C57BL͞6 background were from The Jackson Laboratories; and FcR␥ KO mice on the C57BL͞6 background were from Taconic Farms. B10.S Mt mice were backcrossed five times to the SJL background. All mice were housed under specific pathogen-free conditions (viral antibodyfree) in the Northwestern University Center for Comparative Medicine. Paralyzed animals were afforded easier access to food and water. Peptide-specific IgG1, IgG2b, and IgE levels in sera were determined by sandwich ELISA. Microtiter plates (96-well) were coated with 10 g͞ml peptide in PBS overnight at 4°C. The plates were blocked for 2 h at 37°C with 2% BSA in PBS. Serum was diluted in blocking buffer 1:1,000 for IgG1 and 1:10,000 for IgG2b and incubated in plates overnight at 4°C. Serum was not diluted for measurement of IgE. Antibodies were detected by isotype-specific biotinylated antibodies (Pharmingen) for 2 h at room temperature followed by streptavidin-horseradish peroxidase (Zymed) for 30 min at room temperature. ELISAs were developed with tetramethyl benzidine (BioFX Laboratories, Owings Mills, MD), and absorbance was measured at 450 nm with a VMax microplate reader (Molecular Devices). The percentage of animals showing clinical relapses or symptoms of anaphylaxis between any two groups of mice was analyzed by 2 test using Fisher's exact probability. P values Ͻ 0.05 were considered significant. (Fig. 1a) . At the doses used, only PLP 139 -151-coupled cells proved to be effective at preventing the onset of EAE. In agreement with previous findings, the PLP 139 -151 16-mer (10) and the peptide-coupled cells (11, 19) completely protected against the onset of EAE when administered 7 days after immunization, whereas soluble PLP 139 -151 peptide had no ameliorating effect on disease development (Fig. 1b) . Lastly, we compared the efficiency of the tolerance induction protocols to ameliorate established EAE. PLP 139 -151 -SP treatment reduced disease severity and inhibited the subsequent relapse. Surprisingly, the administration of soluble peptide and soluble peptide oligomer at day 15 after immunization resulted in the death of 80% and 100% of the animals, respectively, within 30 min after treatment (Fig. 1c) . The death-inducing reaction was characterized by ruffled fur, erythema, labored respiration, and unresponsiveness. The mouse receiving soluble PLP 139-151 that did not experience this adverse reaction went on to relapse in a manner similar to the mice receiving the control OVA 323-339 peptide.
Results

Comparison of Soluble Myelin
Soluble Peptide Tolerance Induces Histamine-Dependent Anaphylaxis in Myelin Peptide-Primed Mice. Consistent with an anaphylactic response, body temperature dramatically and rapidly dropped upon administration of soluble PLP 139 -151 to PLP 139 -151 ͞CFA-primed SJL mice in four of five treated animals (Fig. 2a) . In addition, high levels of histamine were detected in the serum of mice within 10 min of injection of PLP 139 -151 (Fig. 2b) . Neither a decrease in body temperature nor histamine release were observed in primed mice treated with soluble OVA 323-339 peptide (data not shown) or PLP 139 -151 -coupled cells ( Fig. 2 a and b). Moreover, treatment with the H1 receptor antagonist tripolidine 30 min before soluble peptide challenge significantly protected the mice from the adverse clinical reaction (Fig. 2c) .
To determine the range of peptides and mouse strains susceptible to induction of anaphylaxis after i.v. peptide tolerance, EAE was induced in SJL, C57BL͞6, and B10.PL mice primed with a variety of known encephalitogenic myelin peptides and mice were treated i.v. with soluble peptides at or shortly after the peak of acute disease (Table 1) 3a). Similar results were obtained with MBP Ac1-11 in B10.PL Mt mice (data not shown). Antibody-dependent anaphylaxis in mice can be mediated by the crosslinking of IgE bound to FcRI on mast cells or by the crosslinking of IgG1 bound to Fc␥RIII on macrophages, mast cells, and͞or other cell types. To confirm that the necessity for functional antibody was due to binding to Fc receptors, FcR␥ KO mice, lacking the shared common FcR␥ chain, were assessed for their ability to undergo peptide-induced anaphylaxis. MOG -primed wt C57BL͞6 mice displayed severe anaphylaxis following administration of soluble MOG after the peak of acute disease (Fig. 3b) . However, FcR␥ KO mice, lacking FcRI and Fc␥RIII, displayed a significant decrease in the incidence of anaphylaxis after the administration of soluble MOG (Fig. 3b) . The two cases of anaphylaxis observed in the FcR␥ KO mice possibly could be due to a direct effect of MOG on the mast cells because it has been shown that whole MBP (21), whole MOG (22) and MOG (M. Brown, personal communication) can cause mast cell degranulation in an antibody-independent manner. Because of the antibody-independent effect of MOG , this peptide was used at a dose of 50 g per mouse, which led to anaphylaxis in MOG -primed mice but not in unprimed wt and KO C57BL͞6 mice (data not shown).
Peptide-Specific IgG1 Is Not Sufficient for Peptide-Induced Anaphylaxis. To determine whether anaphylactic responses correlated with the degree of antibody production to the different myelin peptides and to begin to differentiate between the roles of IgE and IgG1 in myelin peptide-induced anaphylaxis, serum levels of peptide-specific antibodies throughout the EAE disease course were determined in SJL mice primed with PLP 139 -151 , PLP 178 -191 , or MOG 92-106 . Although MOG 92-106 did not prime a potent antibody response, priming with PLP 139 -151 or PLP 178 -191 induced large amounts of specific IgG1 (Fig. 4a) and IgG2b (Fig.  4b) , indicating that the inability of PLP 178 -191 to prime for anaphylaxis is not due to a failure to stimulate class switching and antibody production by B cells and that the presence of antigenspecific IgG1 is not sufficient for peptide-induced anaphylaxis. C57BL͞6 mice primed with PLP 178 -191 also experience clinical EAE and produce large amounts of PLP 178 -191 -specific IgG1 (data not shown) and yet do not succumb to anaphylaxis upon i.v. challenge with soluble peptide (Table 1) . Serum peptidespecific IgE was below the limit of detection in all peptide͞strain combinations assayed (data not shown).
Peptide-Induced Anaphylaxis Depends on IgE͞FcRI but Not IgG1͞
Fc␥RIII. Lastly, we attempted to define the potential roles of the IgG1͞Fc␥RIII and IgE͞FcRI pathways in this model of anaphylaxis. To assess whether functional Fc␥RIII is necessary for anaphylaxis induction, wt C57BL͞6 and Fc␥RIII␣ KOs, which have a targeted mutation in the ␣-chain responsible for binding to the Fc portion of IgG1 but which have functional FcRI, were primed with MOG ͞CFA, challenged with soluble peptide shortly after the peak of acute disease, and monitored for changes in body temperature. Fc␥RIII␣ KO mice underwent anaphylaxis at a similar incidence and severity as wt C57BL͞6 mice (Fig. 5a) , indicating that the presence of Fc␥RIII is not required for myelin peptide-induced anaphylaxis. To definitively investigate the role of the IgE͞FcRI pathway in the anaphylactic response in the absence of commercially available FcRI KO mice, we treated PLP 139 -151 ͞CFA-primed SJL mice with a control antibody or the R1E4 anti-IgE monoclonal antibody (Fig. 5b) , which binds the Fc region of murine IgE, effectively blocking interaction between IgE and FcRI (23), at 7-day intervals starting on the day of priming. Anti-IgE treatment prevented the induction of anaphylaxis upon administration of soluble PLP 139 -151 . This result along with the normal induction of anaphylaxis in Fc␥RIII␣ KOs strongly indicates that the IgE͞FcRI pathway is necessary and sufficient for induction of anaphylaxis following soluble peptide tolerance.
Discussion
Current therapies for autoimmune diseases use various antigennonspecific immunosuppressive and͞or antiinflammatory strategies. Currently, glatiramer acetate (GA), a random polymer of L-alanine, L-glutamic acid, L-lysine, and L-tyrosine, is the only approved therapy for MS that is purported to act in a semiantigen-specific manner (24) . GA is thought to induce T cells that produce T helper 2 cytokines, such as IL-4, IL-5, IL-10, and IL-13, which suppress inflammatory cells (25, 26) . GA treatment requires daily s.c. injections and is beneficial to only a minority of relapsing-remitting MS patients (27) , and 10% of patients experience a transient systemic postinjection reaction characterized by flushing, chest tightness, palpitations, dyspnea, and anxiety (28) . Thus, there is need for new antigen-specific therapies for MS and other autoimmune diseases. Approaches, including oral tolerance and altered peptide ligands, have shown promise in EAE but were not efficacious in subsequent clinical trials (29) (30) (31) , and MBP Ac1-11 . Myelinpeptide induced anaphylaxis occurred by means of an IgEdependent mechanism as anti-IgE antibody administration blocked the induction of anaphylaxis. Anaphylaxis was not observed in Ag-SP-treated mice likely because the cell-bound peptide is unavailable to crosslink antibody bound to Fc receptors on tissue-resident mast cells. IgG1͞Fc␥RIII interactions were neither necessary (anaphylaxis was normally induced in Fc␥RIII␣ KOs) nor sufficient (peptides that do not induce anaphylaxis, e.g., PLP 178 -191 , elicit high levels of peptide-specific IgG1 serum antibody). A possible explanation for the failure of certain peptides inducing high levels of specific IgG1 (e.g., PLP 178 -191 ) to elicit anaphylaxis after i.v. challenge with the homologous soluble peptide is the recent finding that the type of IgG1 induced by priming with peptides in CFA is nonanaphylactic in comparison with the anaphylactic type of IgG1 induced by priming with peptides in alum (32) .
Anaphylaxis has also been observed in murine models in which soluble self-peptide was injected i.p. to induce tolerance during ongoing EAE (33) or by repeated s.c. injections in prediabetic nonobese diabetic (NOD) mice (34). Pedotti et al. (33) reported that myelin peptide-specific IgG1 antibodies accounted for the ability of i.p. administered soluble peptide to cause anaphylaxis during EAE based on the demonstration of increasing amounts of PLP 139 -151 -specific IgG1, but not IgE, in the serum of mice with ongoing EAE. However, those data do not directly demonstrate a role for IgG1, nor do they exclude a role for IgE. In the NOD model, Liu et al. (34) have reported that IgG1 and IgE play a role in s.c. peptide-induced anaphylaxis based on the finding that only coadministration of antibodies blocking Fc␥RII and Fc␥RIII (hybridoma clone 2.4G2) and IgE (hybridoma clone EM95), or coadministration of an H1 Rc antagonist (tripolidine) and a platelet-activating factor antagonist, CV-6209, completely blocked the induction of anaphylaxis. The fact that administration of tripolidine, previously shown to prevent murine IgE-mediated anaphylaxis (16) , alone prevented myelin peptide-induced anaphylaxis in our model lends strong support to the essential role of the IgE͞FcRI pathway. The differences between our findings and those of Liu et al. (34) may be due to the different mouse strains used, spontaneous NOD disease vs. adjuvant-induced EAE, and͞or the different routes of soluble peptide administration.
It is unclear why some encephalitogenic myelin peptides do not trigger anaphylaxis upon i.v. challenge of primed mice with soluble peptide. It has been suggested that self-peptides expressed in the thymus and, therefore, involved in central tolerance induction do not induce anaphylaxis (33) . This hypothesis is not supported by our study demonstrating the equal anaphylactic ability of PLP 139 -151 and MOG , which are not (35, 36) , and MBP Ac1-11 and MBP 84 -104 , which are expressed in the rodent thymus (37) . In addition, the ability of certain myelin peptides to trigger anaphylactic response is clearly not due to the fact that only certain peptides serve as efficient B cell epitopes, because priming with PLP 178 -191 induces large amounts of antigenspecific IgG1 and IgG2b in SJL and C57BL͞6 mice but does not result in anaphylactic shock upon i.v. challenge with soluble peptide. Because the levels of peptide-specific IgE in the serum were below the limit of detection, there may be a quantitative difference in the amount of IgE produced in response to priming with different peptides. Peptide-specific IgE is likely very quickly and avidly bound to FcRI on mast cells, thereby reducing the unbound amount in the serum to undetectable levels. Long-term maintenance of cell surface-bound IgE on mast cells has been described even after serum levels of IgE became undetectable (38) because of IgE-mediated stabilization and up-regulation of FcRI (39) and the slow kinetics of IgE disassociation (40) .
The clinical implications of these findings raise questions about the future use of soluble peptide tolerance therapies to treat autoimmune disease in humans. The potential danger of soluble peptide therapy is illustrated by a recent clinical trial using an MBP 85-99 altered peptide ligand to regulate MS, which was terminated because of systemic hypersensitivity reactions (31) . However, as previously mentioned, glatiramer acetate appears to be well tolerated (38) . In addition, we have shown that the J5 peptide, a peptide inhibitor designed to compete with MBP 85-99 for binding to HLA-DR2 with the ability to also suppress PLP 139 -151 -induced disease in SJL mice (20) , has no harmful effects on mice when administered i.v. during ongoing disease (Table 1) . Obviously, the mechanisms of self-peptideinduced anaphylaxis will need to be further investigated before proceeding with soluble peptide therapies. Significantly, tolerance induction with Ag-SP appears to safely and efficiently prevent and ameliorate established EAE and is not complicated by the induction of anaphylactic shock.
